Literature DB >> 8189499

Transcriptional silencer of the human papillomavirus type 8 late promoter interacts alternatively with the viral trans activator E2 or with a cellular factor.

M May1, K Grassmann, H Pfister, P G Fuchs.   

Abstract

The noncoding region of the highly oncogenic, epidermodysplasia verruciformis-associated human papillomavirus type 8 contains a negative regulatory element (NRE). Quantitative RNase protection analysis confirmed that the NRE sequence acts as a silencer of transcription. A 38-bp sequence upstream of late promoter P7535 down-regulated expression from the homologous P7535 promoter, as well as the heterologous tk gene promoter, independently of its orientation relative to the test promoters. It also reduced gene expression when cloned downstream of the transcription units. Transient expression assays with keratinocytes and fibroblasts of epidermodysplasia verruciformis patients and controls demonstrated that the NRE activity is not cell specific. Gel retardation tests suggested that NRE specifically interacts with only one nuclear factor. Mutational analysis identified three NRE mutants which no longer formed a detectable DNA-protein complex but still repressed transcription, indicating that protein-DNA interaction is not relevant for the silencer function. The NRE contains a binding site of viral trans activator protein E2. It was shown that expression of E2 overrides the inhibitory effect of the NRE sequences. Binding of E2 and that of the cellular factor were mutually exclusive. The bifunctional nature of NRE acting as a silencer and a target site for viral trans activator E2 offers an interesting opportunity to regulate the switch from early to late transcription in the human papillomavirus life cycle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8189499      PMCID: PMC236865     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Transcription of the E6 and E7 genes of human papillomavirus type 6 in anogenital condylomata is restricted to undifferentiated cell layers of the epithelium.

Authors:  T Iftner; M Oft; S Böhm; S P Wilczynski; H Pfister
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 2.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia.

Authors:  M H Schiffman
Journal:  J Natl Cancer Inst       Date:  1992-03-18       Impact factor: 13.506

3.  Complete nucleotide sequence of the Escherichia coli plasmid pBR322.

Authors:  J G Sutcliffe
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1979

4.  Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Authors:  J Fogh; W C Wright; J D Loveless
Journal:  J Natl Cancer Inst       Date:  1977-02       Impact factor: 13.506

Review 5.  Human papillomaviruses and skin cancer.

Authors:  H Pfister
Journal:  Semin Cancer Biol       Date:  1992-10       Impact factor: 15.707

Review 6.  Human papillomaviruses and genital cancer.

Authors:  L Gissmann
Journal:  Semin Cancer Biol       Date:  1992-10       Impact factor: 15.707

7.  NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region.

Authors:  S Kyo; M Inoue; Y Nishio; K Nakanishi; S Akira; H Inoue; M Yutsudo; O Tanizawa; A Hakura
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  A conserved DNA structural control element modulates transcription of a mammalian gene.

Authors:  A J Pierce; R C Jambou; D E Jensen; J C Azizkhan
Journal:  Nucleic Acids Res       Date:  1992-12-25       Impact factor: 16.971

10.  Identification of a negative regulatory domain in the human papillomavirus type 18 promoter: interaction with the transcriptional repressor YY1.

Authors:  T Bauknecht; P Angel; H D Royer; H zur Hausen
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  8 in total

1.  Induction of the human papillomavirus type 31 late promoter requires differentiation but not DNA amplification.

Authors:  Kathryn M Spink; Laimonis A Laimins
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 2.  Human papillomavirus and the development of non-melanoma skin cancer.

Authors:  C A Harwood; J M McGregor; C M Proby; J Breuer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

3.  E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors.

Authors:  F Stubenrauch; I M Leigh; H Pfister
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

4.  Low-affinity E2-binding site mediates downmodulation of E2 transactivation of the human papillomavirus type 8 late promoter.

Authors:  F Stubenrauch; H Pfister
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 5.  The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.

Authors:  Maciej Lazarczyk; Patricia Cassonnet; Christian Pons; Yves Jacob; Michel Favre
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

6.  Both viral E2 protein and the cellular factor PEBP2 regulate transcription via E2 consensus sites within the bovine papillomavirus type 4 long control region.

Authors:  M E Jackson; M S Campo
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 7.  The papillomavirus E2 proteins.

Authors:  Alison A McBride
Journal:  Virology       Date:  2013-07-10       Impact factor: 3.616

8.  UV-B irradiation stimulates the promoter activity of the high-risk, cutaneous human papillomavirus 5 and 8 in primary keratinocytes.

Authors:  B Akgül; W Lemme; R García-Escudero; A Storey; H J Pfister
Journal:  Arch Virol       Date:  2004-10-05       Impact factor: 2.574

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.